Masami Hattori, MD
Pain Medicine · San Francisco, CANPI 1306938055
Payments from drug & device makers
Across 210 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$605
- Indivior Inc.$556
- AbbVie$500
- Lilly USA, LLC$411
- Nevro Corp.$363
- Saluda Medical Americas, Inc.$269
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,38497%
- Education$1183%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 57 | $605 |
| Indivior Inc. | 20 | $556 |
| AbbVie(2 entities) | 22 | $500 |
| Lilly USA, LLC | 17 | $411 |
| Nevro Corp. | 6 | $363 |
| Saluda Medical Americas, Inc. | 2 | $269 |
| Pfizer | 9 | $184 |
| Amgen(2 entities) | 8 | $175 |
| Novartis | 7 | $161 |
| Biodelivery Sciences International, Inc. | 10 | $142 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $131 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $130 |
| Lundbeck LLC | 4 | $103 |
| MDD US Operations, LLC | 5 | $103 |
| Scilex Pharmaceuticals Inc. | 4 | $92 |
| Boston Scientific | 2 | $59 |
| Tersera Therapeutics LLC | 2 | $59 |
| Hikma Pharmaceuticals USA | 3 | $57 |
| IBSA Pharma Inc. | 3 | $48 |
| West Therapeutics Development, LLC | 2 | $42 |
| Biohaven Pharmaceuticals, Inc. | 1 | $39 |
| Stryker | 1 | $37 |
| Zyla Life Sciences, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Kaleo, Inc. | 1 | $23 |
| Assertio Therapeutics, Inc. | 1 | $23 |
| Neuronetics, Inc. | 1 | $22 |
| Globus Medical | 1 | $21 |
| Bausch Health US, LLC | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Shionogi Inc | 1 | $13 |
| Trevena, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Evoke SCS$269
- Senza$154
- Senza Spinal Cord Stimulation System$125
- SUBLOCADE$111
How this compares
$4,502 in reported general payments places this provider in the 65th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 65 | $40,159 |
| Nurtec OdtRimegepant Sulfate | 15 | $27,731 |
| Buprenorphine | 98 | $24,837 |
| BotoxOnabotulinumtoxina | 11 | $11,477 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 91 | $10,692 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 351 | $7,929 |
| Lidocaine | 32 | $6,793 |
| Gabapentin | 175 | $4,177 |
| Oxycodone Hcl | 154 | $2,182 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 77 | $1,682 |
| Morphine Sulfate ErMorphine Sulfate | 52 | $1,473 |
| Pregabalin | 40 | $1,447 |
| Tramadol Hcl ErTramadol Hcl | 19 | $1,368 |
| Buprenorphine Hcl | 37 | $1,122 |
| Duloxetine Hcl | 49 | $1,058 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca | $605 | $40,15965 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone, Buprenorphine Hcl | $57 | $36,650226 claims |
| PfizerNurtec Odt | $184 | $27,73115 claims |
| AbbVieBotox | $500 | $11,47711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 840 pain medicine providers in California.
Other pain medicine in San Francisco
- Eric GrigsbyNapa$3.2M
- Jason PopeSanta Rosa$2.8M
- Javid GhandehariSanta Monica$2.7M
- Alexander HerselThousand Oaks$2.1M
- Krishnan ChakravarthyTemecula$1.9M
- Kasra AmirdelfanWalnut Creek$1.7M
- Ramana NaiduLarkspur$1.6M
- Foead GeulaStudio City$1.3M
- Xiang QianRedwood City$941K
- Jacqueline WeisbeinNapa$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.